| TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients (NCT04561986) | Vastra Gotaland Region | 2022-02-01 |
| Incidence, Course and Outcome of ABMR in Kidney Transplantation (NCT05140018) | University Medical Center Groningen | 2022-01-01 |
| Felzartamab in Late Antibody-Mediated Rejection (NCT05021484) | Farsad Eskandary | 2021-10-06 |
| Biorepository and Registry for Plasma Exchange Patients (NCT05004493) | Charles M Knudson | 2021-07-28 |
| MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT) (NCT05184426) | Juan Francisco Delgado Jimenez | 2021-04-01 |
| DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients (NCT04368962) | First Affiliated Hospital Xi'an Jiaotong University | 2021-01-22 |
| Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT (NCT04541914) | Seoul National University Hospital | 2020-05-19 |
| Desensitization in Kidney Allograft Using Daratumumab (NCT04204980) | Assistance Publique - Hôpitaux de Paris | 2020-02-18 |
| Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation (NCT03388008) | Washington University School of Medicine | 2019-12-17 |
| Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR (NCT03737136) | Shahid Beheshti University of Medical Sciences | 2019-11-01 |
| Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (NCT03744910) | CSL Behring | 2019-10-14 |
| Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection (NCT04367610) | Istanbul University | 2019-09-01 |
| DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection (NCT03702257) | University Hospital, Strasbourg, France | 2019-08-23 |
| Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation (NCT04026087) | University Hospital, Montpellier | 2019-07-18 |
| Transplant Antibody-Mediated Rejection: Guiding Effective Treatments (NCT03994783) | Imperial College London | 2019-07-17 |
| Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization (NCT03805178) | Duke University | 2019-05-01 |
| Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange (NCT03436134) | University Hospital, Grenoble | 2018-07-01 |
| Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation (NCT03474536) | University Hospital, Bordeaux | 2018-03-14 |
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant (NCT03380962) | Stanley Jordan, MD | 2018-02-27 |
| Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant (NCT03380377) | Stanley Jordan, MD | 2018-02-21 |
| Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response (NCT03430414) | Thomas Mueller | 2018-02-15 |
| A Pilot Trial of Clazakizumab in Late ABMR (NCT03444103) | Medical University of Vienna | 2018-01-16 |
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients (NCT03221842) | CSL Behring | 2017-11-06 |
| VIRTUUS Children's Study (NCT03719339) | Children's Hospital of Philadelphia | 2017-08-10 |
| HPA Antibodies and the Distribution of Antigen and Antibodies (NCT03408158) | Guangzhou First People's Hospital | 2017-01-01 |
| Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study (NCT02120482) | Medical University of Vienna | 2014-10-01 |
| Belatacept in Kidney Transplantation of Moderately Sensitized Patients (NCT02130817) | University of Wisconsin, Madison | 2014-09-24 |
| Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (NCT01873157) | Medical University of Vienna | 2013-12-01 |
| Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation (NCT01895127) | Brigham and Women's Hospital | 2013-11-01 |
| Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants (NCT01630538) | University of Manitoba | 2013-06-01 |
| The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation (NCT02013037) | Cedars-Sinai Medical Center | 2012-11-01 |
| Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation (NCT01848301) | Gladwin, Mark, MD | 2012-09-01 |
| Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization (NCT01399593) | Alexion Pharmaceuticals, Inc. | 2011-11-02 |
| Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange (NCT02533596) | Hannover Medical School | 2010-09-01 |
| Development and Validation of HistoMX, a Gene-Expression Platform for Molecular Interpretation of Kidney Allograft Biopsies (NCT07700563) | Paris Translational Research Center for Organ Transplantation | 2004-01-01 |
| Antibodies and Liver Retransplantation (NCT03815864) | London Health Sciences Centre | 1977-01-01 |